Hydroxyethyl starch 130 kd/0.4 and albumin improve CVVH biocompatibility whereas gelatin and hydroxyethyl starch 200 kd/0.5 lead to adverse side effects of CVVH in anesthetized pigs

Shock

Volumn 25, Issue 5, 2006, Pages 533-545

  Unger, Juliane K ^a   Haltern, Claudia ^b   Kobela, Jana Bara ^a   Francis, Roland ^a   Rossaint, Rolf ^b   Grosse Siestrup, Christian ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Colloids; Fluid resuscitation; Haemocompatibility; Hemofiltration; Porcine model; Sepsis

Indexed keywords

ALBUMIN; GELATIN; HETASTARCH;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOCOMPATIBILITY; CENTRAL VENOUS PRESSURE; COLLOID; CONTINUOUS HEMOFILTRATION; CONTROLLED STUDY; CRITICAL ILLNESS; FEMALE; FLUID THERAPY; HEART RATE; HEMODYNAMIC MONITORING; KIDNEY FUNCTION; LUNG ARTERY PRESSURE; LUNG CAPILLARY PRESSURE; LUNG FUNCTION; LUNG VASCULAR RESISTANCE; MEAN ARTERIAL PRESSURE; NONHUMAN; POSITIVE END EXPIRATORY PRESSURE; SEPSIS; SWINE; SYSTEMIC VASCULAR RESISTANCE;

ALBUMINS; ANIMALS; BIOCOMPATIBLE MATERIALS; BLOOD PLATELETS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GELATIN; HEMODYNAMIC PROCESSES; HEMOFILTRATION; HEMOGLOBINS; HETASTARCH; HUMANS; LUNG; PLASMA SUBSTITUTES; SWINE;

EID: 33646780621     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.shk.0000221322.98590.99     Document Type: Article

References (40)

1. Moran M, Kapsner C: Acute renal failure associated with elevated plasma oncotic pressure. N Engl J Med 317:78-50, 1987.
2. Bunn F, Alderson P, Hawkins V: Colloid solutions for fluid resuscitation. Cochrane Database Syst Rev (1):CD001319, 2003.
3. Alderson P, Bunn F, Lefebvre C, Li Wan Po A, Roberts I, Schierhout G: Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database Syst Rev (4):CD001208, 2004.
4. Finfer S, Bellomo R, Boyce N, French J, Myburgh J, Norton R: SAFE Study Investigators: a comparison of albumin and saline for fluid resuscitation in the intensive care unit. N Engl J Med 27:2247-2256, 2004.
5. Boldt J, Priebe H-J: Intravascular volume replacement therapy with synthetic colloids: is there an influence on renal function? Anesth Analg 96:376-382, 2003.
6. Egli GA, Zollinger A, Seifert B, Popovic D, Pasch T, Sphan DR: Effect of progressive haemodilution with hydroxyethylstarch, gelatin and albumin on blood coagulation. Br J Anaesth 78:684-668, 1997.
7. Strauss RG, Stump DC, Henriksen RA, Saunders R: Effects of hydroxyethyl starch on fibrinogen, fibrin clot formation, and fibrinolysis. Transfusion 25:230-234, 1985.
8. Langeron O, Doelberg M, Ang ET, Bonnet F, Capdevila X, Coriat P: Voluven®, a lower substituted novel hydroxyethyl starch (HES 130/0.4), causes fewer effects on coagulation in major orthopedic surgery than HES 200/ 0.5. Anesth Analg 92:855-862, 2001.
9. Rafie AD, Rath PA, Michell MW, Kirschner RA, Deyo DJ, Prough DS, Grady JJ, Kramer GC: Hypotensive resuscitation of multiple hemorrhages using crystalloid and colloids. Shock 22:262-269, 2004.
10. Walter JM, Brundage SI, Todd SR, Zautke NA, Stefater JA, Lam JC, Muller PJ, Malinoski D, Schreiber MA: Resuscitation with lactated Ringer's does not increase inflammatory response in a swine model of uncontrolled hemorrhagic shock. Shock 22:283-287, 2004.
11. Bottoms G, Fessler J, Murphey E, Jonson M, Latshaw H, Mueller B, Clark W, Macias W: Efficacy of convective removal of plasma mediators of endotoxic shock by continuous veno-venous hemofiltration. Shock 5:149-154, 1996.
12. Brophy PD, Somers MJG, Baum MA, Symons JM, McAfee N, Fortenberry JD, Rogers K, Barnett J, Blowey D, Baker C, Bunchman TE, Goldstein SL: Multi-centre evaluation of anticoagulation in patients receiving continuous renal replacement therapy (CRRT). Nephrol Dial Transplant 20:1416-1421, 2005.
13. Marx G, Cobas Meyer M, Schuerholz T, Vangerow B, Gratz KF, Hecker H, Suempelmann R, Rueckoldt H, Leuwer M: Hydroxyethyl starch and modified fluid gelatin maintain plasma volume in a porcine model of septic shock with capillary leakage. Intensive Care Med 28:629-635, 2002.
14. Pries AR, Secomb TW, Sperandio M, Gaehtgens P: Blood flow resistance during hemodilution: effect of plasma composition. Cardiovasc Res 37:225-235, 1998.
15. Harrison MJ: Influence of haematocrit in the cerebral circulation. Cerebrovasc Brain Metab Rev 1:55-67, 1989.
16. Freyburger G, Dubreuil M, Boisseau MR: Rheological properties of commonly used plasma substitutes during preoperative normovolaemic acute haemodilution. Br J Anaesth 76:519-525, 1996.
17. Suempelmann R, Guenther A, Zander R: Haemoconcentration by gelatin-induced acceleration of erythrocyte sedimentation rate. Anesthesia 55:217-220, 2000.
18. Unger JK, Janssen VR, Kashefi A, Haltern C, Klosterhalfen B, Fischer Y, Gressner AM, Rossaint R: Enhancing Filtration rates by the use of blood flow around the capillaries of plasmafilters - an in vitro study. Int J Artif Organs 11:821-831, 2001.
19. Unger JK, Horn NA, Kashefi A, Blumberg A, Klosterhalfen B, Rossaint R: The influence of hypoalbuminemia on maximal flow rates and transmembrane pressure during plasmapheresis - an in vitro study. Blood Purif 19:408-416, 2001.
20. Unger JK, Haltern C, Dohmen B, Gressner A, Grosse-Siestrup C, Groneberg DA, Rossaint R: Albumin and hydroxyethyl starch 130kD/0.4 improve filter clearance and hemocompatibility in hemo- and plasmafiltration - an in vitro study. Nephrol Dial Transplant 20:1922-1931, 2005.
21. Eger EI 2nd, Johnson BH, Weiskopf RB, Holmes MA, Yasuda N, Targ A, Rampil IJ: Minimum alveolar concentration of I-653 and isoflurane in pigs: definition of a supramaximal stimulus. Anesth Analg 67:1174-1176, 1988.
22. Schnoor J, Schreck R, Baumert JH, Grosse-Siestrup C, Rossaint R, Unger JK: Influence of differences in body weight and volume management on experimental results in porcine models. Int J Artif Organs 27:924-934, 2004.
23. Laffey JG, Croinin DO, Mcloughlin P, Kavanagh BP: Permissive hypercapnia - role in protective lung ventilatory strategies. Intensive Care Med 30:347-356, 2004.
24. Maeda N, Shiga T: Opposite effect of albumin on the erythrocyte aggregation induced by immunoglobulin G and fibrinogen. Biochem Biophys Acta 855:127-135, 1986.
25. Stefanidis I, Heintz B, Frank D, Mertens PR, Kierdorf HP: Influence of hematocrit on hemostasis in continuous venovenous hemofiltration during acute renal failure. Kidney Int Suppl 72:S51-S55, 1999.
26. Suempelmann R, Schuerholz T, Marx G, Thorns E, Hausdorfer J: Haemodynamic, acid-base and electrolyte changes during plasma replacement with hydroxyethyl starch or crystalloid solution in young pigs. Paediatr Anaesth 10:173-179, 2000.
27. Bellomo R, Honore PM, Matson J, Ronco C, Winchester J: Extracorporeal blood treatment (EBT) methods in SIRS/sepsis. Int J Artif Organs 28:450-458, 2005.
28. Pinhu L, Whitehead T, Evans T, Griffiths M: Ventilator-associated lung injury. Lancet 361:332-340, 2003.
29. Su F, Nguyen ND, Creteur J, Cai Y, Nagy N, Anh-Dung H, Amaral A, Bruzzi de Carvalho F, Chochrad D, Vincent JL: Use of low tidal volume in septic shock may decrease severity of subsequent acute lung injury. Shock 22:145-150, 2000.
30. Lee CC, Chang IJ, Yen ZS, Hsu CY, Chen SY, Su CP, Chiang WC, Chen SC, Chen WJ: Effect of different resuscitation fluids on cytokine response in a rat model of hemorrhagic shock. Shock 24:177-181, 2005.
31. Molnár Z, Mikor A, Leiner T, Szakmany T: Fluid resuscitation with colloids of different molecular weight in septic shock. Intensive Care Med 30:1356-1360, 2004.
32. Allison KP, Gosling P, Jones S, Pallister I, Porter KM: Randomized trial of hydroxyethyl starch versus gelatin for trauma resuscitation. J Trauma 47:1114-1121, 1999.
33. Marx G, Pedder S, Smith L, Swaraj S, Grime S, Stockdale H, Leuwer M: Resuscitation from septic shock with capillary leakage: hydroxyethyl starch (130 kD), but not Ringer's solution maintains plasma volume and systemic oxygenation. Shock 21:336-341, 2004.
34. Van der Sande FM, Kooman JP, Barendregt JNM, Nieman FHM, Leunissen KLM: Effect of intravenous saline, albumin, or hydroxyethylstarch on blood volume during combined ultrafiltration and hemodialysis. J Am Soc Nephrol 10:1303-1308, 1999.
35. Jungheinrich C, Scharpf R, Wargenau M, Bepperling F, Baron JF: The pharmacokinetics and tolerability of an intravenous infusion of new hydroxyethyl starch 130/0.4 (6%, 500 mL) in mild-to-severe renal impairment. Anesth Analg 3:544-551, 2002.
36. Bambauer R, Stolz D, El-Saadi R, Stelzer K, Jutzler GA: Behavior of oxypolygelatine (Gelifundol) in patients with dialysis-dependent kidney failure. Infusionsther Klin Ernahr 11:157-160, 1984.
37. Kohler H, Zschiedrich H, Lifante A, Appel F, Pitz H, Clasen R: The elimination of hydroxyethyl starch 200/0.5, dextran 40 and oxypolygelatine. Klin Wochenschr 60:293-301, 1982.
38. Schortgen F, Lacherade J-C, Bruneel F, Cattaneo I, Hemery F, Lemaire F, Brochard L: Effects of hydroxyethyl starch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 357:911-916, 2001.
39. Vincent JL, Laterre PF, Cohen J, Burchadi H, Bruining H, Lerma FA, Wittebole X, De Backer D, Brett S, Dolores M, Nakamura H, John S: A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 23:400-405, 2005.
40. Bengsch S, Boos KS, Nagel D, Seidel D, Inthron D: Extracorporeal plasma treatment for the removal of endotoxin in patients with sepsis: clinical results of a pilot study. Shock 23:494-500, 2005.